Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Entero Healthcare Solutions IPO
Price Band
₹1195.0–1258.0
Issue Size
₹1600.0 Cr
Lot Size
11 shares
Min Investment
₹13,838
GMP
+₹2.0 (0.16%)
Issue Price
₹1258.0
Entero Healthcare Solutions IPO AI Summary
- Entero Healthcare Solutions IPO is listed on BSE, NSE in the Pharmacy Retail sector.
- Price band: ₹1195.0–₹1258.0 per share, lot size 11 shares (min. investment ₹13,838).
- Subscription window: 09 Feb–13 Feb 2024, listing on 16 Feb 2024.
- Current GMP is +₹2.0 (0.16%), an estimated listing price of ₹1260 — unofficial and can change daily.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Entero Healthcare Solutions IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 13 Feb 2024 — not a current signal.
Reviewers are split — see individual calls below.
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Entero Healthcare Solutions IPO Grey Market Premium (GMP) Today
GMP
+₹2.0
GMP %
+0.16%
Est. Listing
₹1260.0
Updated: 25 Jul 2026 14:07
About the Company
Incorporated in 2018, Entero Healthcare Solutions Limited is a distributor of healthcare products in India. The company's technology-driven platform provides healthcare product distribution services to pharmacies, hospitals, and clinics throughout India. During the fiscal years 2021, 2022, and 2023, the company served over 39,500, 64,200, and 81,400 retail customers, respectively. Additionally, they also served over 1,600, 2,500, and 3,400 hospital customers during the same period. Entero Healthcare Solutions has relationships with over 1,900 healthcare product manufacturers, giving them access to over 64,500 product stock-keeping units as of March 31, 2023. The company has 73 warehouses in 37 cities across 19 states and union territories, and its customer base includes over 81,400 pharmacies and 3,400 hospitals in 495 districts as of March 31, 2023. This provides excellent access to healthcare product manufacturers. As of 31st March, 2023, the company employs a total of 3014 people in various departments.
Company Financials (₹ Cr)
As of 2023-09-30
| Period Ended | 30 Sep 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 1,505.95 | 1,308.73 | 1,125.98 | 833.79 |
| Total Income | 1,898.98 | 3,305.72 | 2,526.55 | 1,783.67 |
| Profit After Tax | 11.64 | -11.10 | -29.44 | -15.35 |
| NET Worth | 660.54 | 597.66 | 563.22 | 487.06 |
| Total Borrowing | 488.68 | 373.52 | 285.03 | 141.70 |
Key Ratios
EPS
₹0.00
NAV
₹174.21
ROE
-2.66%
ROCE
6.06%
RoNW
-1.86%
P/B Value
7.22
P/E Ratio
0
Market Cap
₹3021.21 Cr
PAT Margin
4.69%
Debt/Equity
0.45
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Medplus Health Services Limited | 124.93 | 3.36% | 177.21 | 4.17 | 4.17 |
| Entero Healthcare Solutions Limited This IPO | 174.21 | -1.86% | — | -3.43 | -3.43 |
Promoters
Prabhat Agrawal, Prem Sethi and OrbiMed Asia III Mauritius Ltd.
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Repayment/prepayment, in full or part, of certain borrowings availed of by our Company 142.50 2 Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026 480.00 3 General corporate purposes 91.70 4 Pursuing inorganic growth initiatives through acquisitions 237.00 Total 951.20
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹1,783.67 Cr in the year ending 31 Mar 2021, rising to ₹2,526.55 Cr by 31 Mar 2022, and further increasing to ₹3,305.72 Cr by 31 Mar 2023. However, for the most recent period ending 30 Sep 2023, total income decreased to ₹1,898.98 Cr, though this is a 9-month figure, not a full year, so isn't directly comparable.
Profit Trend
The profit after tax was a loss of ₹15.35 Cr in the year ending 31 Mar 2021, worsening to a loss of ₹29.44 Cr by 31 Mar 2022. By 31 Mar 2023, the loss narrowed to ₹11.10 Cr, and in the most recent period ending 30 Sep 2023, the company reported a profit after tax of ₹11.64 Cr.
Valuation
At the issue price of ₹1258.0, Entero Healthcare Solutions has an implied P/E ratio of 0, as the EPS is negative. In comparison, peers like Medplus Health Services Limited have a P/E ratio of 177.21.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing gain of an IPO. A positive GMP suggests that the IPO is likely to list at a higher price than its issue price, while a negative GMP indicates the opposite. Investors often look at the GMP to gauge market sentiment towards the IPO before it lists.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their risk tolerance and investment goals. It's important to consider the company's financial health and market position before making any decisions.
Who May Want to Wait
Investors who are risk-averse or those who prefer stable, established companies may want to avoid IPOs like this, especially given the company's recent financial performance and the potential for volatility in the healthcare sector.
IPO Timeline, Explained
The IPO opens for subscription on February 9, 2024, and closes on February 13, 2024. Allotment of shares will be done on February 14, 2024, and the shares are expected to be listed on February 16, 2024.
Listing Gains — The Risk
Listing gains refer to the potential profit an investor can make when selling shares on the first day of trading. However, these gains are not guaranteed and can be influenced by various factors, including market conditions and investor sentiment. It's important to be aware of the risks involved in trading on listing day.
This evaluation is generated from Entero Healthcare Solutions's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Entero Healthcare Solutions IPO GMP today?
Entero Healthcare Solutions IPO GMP today is +₹2.0 (0.16%), indicating an estimated listing price of ₹1260. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Entero Healthcare Solutions IPO?
The price band of Entero Healthcare Solutions IPO is ₹1195.0–₹1258.0 per share.
When does Entero Healthcare Solutions IPO open and close?
Entero Healthcare Solutions IPO opens on 09 February 2024 and closes on 13 February 2024.
When does Entero Healthcare Solutions IPO list on the stock exchange?
Entero Healthcare Solutions IPO listed on 16 February 2024 at ₹1260.0.
What is the lot size for Entero Healthcare Solutions IPO?
The lot size for Entero Healthcare Solutions IPO is 11 shares, requiring a minimum investment of ₹13,838.
What is the lot size for this IPO?
The lot size for Entero Healthcare Solutions IPO is 11 shares.
What is the minimum investment required?
The minimum investment required for this IPO is ₹13,838.0.
What is the price band for this IPO?
The price band for Entero Healthcare Solutions IPO is ₹1195.0 to ₹1258.0.
When is the listing date for this IPO?
The listing date for Entero Healthcare Solutions IPO is February 16, 2024.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected listing gain of an IPO.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
09 Feb 2024
Close
13 Feb 2024
Allotment
14 Feb 2024
Listing
16 Feb 2024
Similar IPOs in Pharmacy Retail
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Entero Healthcare Solutions?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.